Drugs to fight breast cancer near approval
Article Abstract:
Zeneca Inc. and Genentech Inc. both won approval recommendations for their anti-breast cancer drugs. An FDA advisory panel recommended approval of Zeneca's tamoxifen for use in reducing the risk of breast cancer. Tamoxifen was already approved for preventing breast cancer recurrences, but can now be marketed to women who have never had cancer. The panel was careful to stress that the drug's risks made it suitable only for women at extremely high risk of developing breast cancer. The committee also advised approval of the Genentech drug Herceptin, a genetically engineered monoclonal antibody which slows progression of advanced metastic breast cancer.
Comment:
Zeneca's Tamoxifen recommended for FDA approval for breast cancer risk reduction
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
FDA approves a drug that blocks a gene
Article Abstract:
Fomivirsen, a new drug that is used in the treatment of the CMV retinitis virus, has been given approval by the Food and Drug Administration. Isis Pharmaceuticals Inc., a bio-technology firm that is based in Carlsbad, California, will produce the drug for use by AIDS patients under the brand name, Vitravene. The drug will be marketed by Novartis AG, the Swiss-based pharmaceutical company, through its eye-care unit, Ciba Vision Corporation. Industry analysts have said that the new drug's market will be valued at less than $20 million.
Comment:
FDA has approved Fomivirsen, a new drug from ISIS that is used in the treatment of the CMV retinitis virus
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Eli Lilly to pay Sepracor $90 million to license drug; antidepressant is enhanced form of Prozac
Article Abstract:
Sepracor will receive $90 million from Eli Lilly & Co. in a licensing deal for a purer form of the antidepressant Prozac. Prozac, with worldwide 1997 sales of $2.6 billion, will no longer be protected by patents starting in 2001; the newer version, R-fluoxetine, will be protected until 2015. Sepracor's technology involves reducing the side effects of the drug; it is still in clinical trials that are hoped to be completed in 2001.
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Board gives final approval to new rule on derivatives. U.S. censures a major firm on its auditing. For Sony, too little information proved to be a dangerous thing
- Abstracts: Ford uses aggressive marketing approach in Thailand. Under pressure, GM takes its sales show on the road. GM puts strikes' cost at $1.18 billion, above analysts' estimates
- Abstracts: Compaq reports small profit before charges. Apple's $101 million net tops estimates. Data General expects $125 million charge for restructuring
- Abstracts: Mitsubishi will pay $34 million in sexual-harassment settlement. Platinum Technology agrees to acquire Memco Software in a $437 million deal
- Abstracts: Bankruptcy judge approves $25 milion loan for Livent. Livent gets $5 million from board; troubled company seeks more funds